Arena Pharmaceuticals to Provide Corporate Update and Release Fourth Quarter and Full-Year 2016 Financial Results on Tuesday,...
March 06 2017 - 4:30PM
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), today announced that the
Company will provide a corporate update and release its fourth
quarter and full-year 2016 financial results on Tuesday, March 14,
2017, after the close of the U.S. financial markets. The
Company will host a conference call and live webcast with the
investment community the same day at 4:30 p.m. ET.
Conference Call & Webcast
InformationWhen: March 14, 2017, 4:30 p.m. ETDial-in:
(877) 643-7155 (United States) or (914) 495-8552
(International)Conference ID: 80816089
Please join the conference call at least 10
minutes early to register. You can access the live webcast
under the investor relations section of Arena’s website at:
www.arenapharm.com. A replay of the conference call will be
archived under the investor relations section of Arena’s website
for 30 days shortly after the call.
About Arena
PharmaceuticalsArena Pharmaceuticals is a
biopharmaceutical company focused on developing novel, small
molecule drugs across multiple therapeutic areas. Arena is focused
on three primary proprietary investigational clinical programs:
etrasimod (APD334) in Phase 2 evaluation for multiple autoimmune
conditions, ralinepag (APD811) in Phase 2 evaluation for pulmonary
arterial hypertension (PAH), and APD371 entering Phase 2 evaluation
for the treatment of pain associated with Crohn's disease. In
addition, Arena has collaborations with the following
pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc.
(commercial stage), Axovant Sciences (Phase 2 candidate), and
Boehringer Ingelheim International GmbH (preclinical
candidate).
Forward-Looking
StatementsCertain statements in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Such forward-looking statements include statements
Arena’s focus, primary programs and collaborations. For such
statements, Arena claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Arena’s expectations. Factors that could cause
actual results to differ materially from the forward-looking
statements include those disclosed in Arena’s filings with the
Securities and Exchange Commission. These forward-looking
statements represent Arena’s judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Contact:
Kevin R. Lind, Chief Financial Officer
klind@arenapharm.com
858.210.3636
Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From Sep 2023 to Sep 2024